GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ReNeuron Group PLC (LSE:RENE) » Definitions » Earnings per Share (Diluted)

ReNeuron Group (LSE:RENE) Earnings per Share (Diluted) : £-0.09 (TTM As of Sep. 2023)


View and export this data going back to 2005. Start your Free Trial

What is ReNeuron Group Earnings per Share (Diluted)?

ReNeuron Group's Earnings per Share (Diluted) for the six months ended in Sep. 2023 was £-0.05. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.09.

ReNeuron Group's EPS (Basic) for the six months ended in Sep. 2023 was £-0.05. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.09.

ReNeuron Group's EPS without NRI for the six months ended in Sep. 2023 was £-0.05. Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 was £-0.09.

During the past 3 years, the average EPS without NRIGrowth Rate was 36.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 29.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 30.20% per year.

During the past 13 years, ReNeuron Group's highest 3-Year average EPS without NRI Growth Rate was 82.90% per year. The lowest was -267.60% per year. And the median was 18.65% per year.


ReNeuron Group Earnings per Share (Diluted) Historical Data

The historical data trend for ReNeuron Group's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ReNeuron Group Earnings per Share (Diluted) Chart

ReNeuron Group Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Earnings per Share (Diluted)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.44 -0.36 -0.29 -0.17 -0.10

ReNeuron Group Semi-Annual Data
Mar14 Sep14 Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Earnings per Share (Diluted) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.09 -0.08 -0.06 -0.04 -0.05

Competitive Comparison of ReNeuron Group's Earnings per Share (Diluted)

For the Biotechnology subindustry, ReNeuron Group's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ReNeuron Group's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ReNeuron Group's PE Ratio distribution charts can be found below:

* The bar in red indicates where ReNeuron Group's PE Ratio falls into.



ReNeuron Group Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

ReNeuron Group's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2023 is calculated as

Diluted Earnings Per Share (A: Mar. 2023 ) = (Net Income - Preferred Dividends) / Shares Outstanding (Diluted Average)
=(-5.408-0)/57.126
=-0.09

ReNeuron Group's Earnings Per Share (Diluted) for the quarter that ended in Sep. 2023 is calculated as

Diluted Earnings Per Share (Q: Sep. 2023 )=(Net Income - Preferred Dividends / Shares Outstanding (Diluted Average)
=(-2.841-0)/57.174
=-0.05

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.


ReNeuron Group  (LSE:RENE) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


ReNeuron Group Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of ReNeuron Group's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.


ReNeuron Group (LSE:RENE) Business Description

Traded in Other Exchanges
Address
Pencoed Business Park, Pencoed, Bridgend, GBR, CF35 5HY
ReNeuron Group PLC is engaged in the field of biotechnology. Its core activities include the research and clinical development of cell-based therapeutics. The company product pipeline includes the human retinal progenitor cell line (hRPC) and CTX neural cell line. It derives revenue from UK and U.S. The company is mainly focusing on the treatment of stroke disability, inherited retinal diseases, and cancer.

ReNeuron Group (LSE:RENE) Headlines